Allied Market Research published a report, titled, “Human Insulin Market by Product Type (Pens, Syringes and Others), Indication (Type 1 Diabetes, Type 2 Diabetes and Gestational Diabetes), Type of Insulin (Rapid-acting Insulin, Short-acting Insulin, Intermediate-acting Insulin, and Others), and Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Providers) : Global Opportunity Analysis and Industry Forecast, 2024-2033″. According to the report, the human insulin market was valued at $17.1 billion in 2023, and is estimated to reach $24.0 billion by 2033, growing at a CAGR of 3.4% from 2024 to 2033.
Key Takeaways
- The human insulin market share study covers 20 countries. The research includes a segment analysis of each country in terms of value for the projected period.
- More than 1, 500 product literatures, industry releases, annual reports, and other such documents of major human insulin industry participants along with authentic industry journals, trade associations’ releases, and government websites have been reviewed for generating high-value industry insights.
- The study integrated high-quality data, professional opinions and analysis, and critical independent perspectives. The research approach is intended to provide a balanced view of global markets and to assist stakeholders in making educated decisions in order to achieve their most ambitious growth objectives.
Emerging Trends
- Shift Toward Biosimilar Insulins: The introduction of biosimilar insulin products offers cost-effective alternatives, increasing accessibility and fostering market competition.
- AI Integration in Insulin Therapy: Artificial intelligence is being utilized to enhance insulin dosing recommendations and therapy outcomes, leading to more personalized diabetes management.
- Phasing Out of Human Insulin Pens: Novo Nordisk announced plans to gradually discontinue the production of human insulin pens globally, shifting focus to vials and newer therapies. This move has raised concerns about accessibility in low-income regions.
Request Sample of the Report on – https://www.alliedmarketresearch.com/request-sample/417
Increasing prevalence of diabetes, rise in awareness and screening programs for diabetes, and rise in R&D activities are the major factors that drive the growth of the human insulin market growth. However, side effects associated with insulin therapy restricts the market growth. Moreover, innovations in insulin delivery systems, such as insulin pumps, and smart pens offers remunerative opportunities for the expansion of the global human insulin market.
Segment Highlights
Pens segment to maintain its leadership status during the forecast period
By product type, pens segment dominated the market share in 2023. This is attributed to the fact that insulin pens offer superior convenience and ease of use compared to traditional vial-and-syringe methods which drives the segment growth. Their design allows for more accurate dosing, which is particularly beneficial for patients requiring precise insulin management. In addition, technological advancements led to the development of smart insulin pens, which can track dosing history, provide reminders, and sync with mobile applications, thereby enhancing diabetes management and segment growth.
The type-1 diabetes segment to maintain its leadership status during the forecast period
By indication, type-1 diabetes segment dominated the market share in 2023. Type-1 diabetes necessitates lifelong insulin therapy since the body ceases to produce insulin naturally, making insulin a critical and non-negotiable treatment for these patients. This creates a consistent and ongoing demand for insulin products. In addition, advancements in insulin delivery technologies, such as continuous glucose monitors (CGMs) and insulin pumps, are particularly beneficial for type-1 diabetes management, enhancing treatment adherence and improving quality of life thereby driving the segment growth.
The rapid acting insulin segment to maintain its leadership status during the forecast period
By type of insulin, rapid acting insulin segment dominated the market share in 2023. The increasing prevalence of diabetes, particularly type 1 diabetes, necessitates immediate and efficient glycemic control, which rapid-acting insulins are designed to provide thereby propelling the segment growth. These insulins offer the advantage of quick onset of action, typically within 15 minutes, making them highly effective for managing postprandial blood sugar spikes. Additionally, advancements in insulin formulations have led to the development of ultra-rapid-acting insulins that further enhance convenience and adherence for patients by allowing for more flexible dosing around meal times which further supports the segment growth.
The drug stores and retail pharmacies segment to maintain its leadership status during the forecast period
By end user, drug stores and retail pharmacies segment dominated the market share in 2023. Retail pharmacies often offer personalized services, such as patient counseling and education on proper insulin use, which enhances patient compliance and outcomes. These pharmacies also tend to have established relationships with local communities, fostering trust and loyalty among customers. In addition, the ability to purchase insulin without extensive wait times or the need for appointments, as required in some healthcare settings, further drives the preference for retail pharmacies.
Regional Outlook
North America to maintain its dominance by 2033
North America is poised to maintain its leadership status in the human insulin market during the forecast period owing to rise in prevalence of diabetes, advanced healthcare infrastructure and significant healthcare expenditure, facilitating widespread access to diabetes management resources and innovative insulin delivery technologies. The presence of leading pharmaceutical companies and ongoing research and development activities further bolster the market, ensuring a continuous pipeline of advanced insulin formulations and delivery systems. However, Asia-Pacific is expected to register the highest CAGR during the forecast period, owing to increase in the prevalence of diabetes, advancements in biotechnology, and the introduction of cost-effective biosimilar insulins.
Key Players
- Eli Lilly and Company
- Sanofi
- Novo Nordisk A/S
- Pfizer
- Biocon
- Wockhardt
- MannKind Corporation
- Tonghua Dongbao Pharmaceutical Co., Ltd.
- Medtronic
- Lupin
You may Also Like
Bone Grafts and Substitutes Market to See Huge Growth by 2033: NuVasive, Inc., Orthofix Holdings
Microtome Market Size, Share, Competitive Landscape and Trend Analysis Report 2033
Contact Details:
David Correa
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
